We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+9.56%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$362M
AUM Growth
+$9.59M
Cap. Flow
-$13M
Cap. Flow %
-3.59%
Top 10 Hldgs %
55.78%
Holding
86
New
3
Increased
22
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$1.71M
2
BCAX
Bicara Therapeutics
BCAX
+$1.25M
3
CMPX icon
Compass Therapeutics
CMPX
+$1.09M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$1.02M
5
INGN icon
Inogen
INGN
+$992K

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.17M
2
MRUS
Merus
MRUS
+$2.96M
3
TSVT
2seventy bio
TSVT
+$2.12M
4
KALV
KalVista Pharmaceuticals
KALV
+$2.09M
5
RGLS
Regulus Therapeutics
RGLS
+$1.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRDF icon
76
Cardiff Oncology
CRDF
$74.3M
– –
-150,000
Closed -$471K
LCTX icon
77
Lineage Cell Therapeutics
LCTX
$284M
– –
-2,511,374
Closed -$1.13M
RGLS
78
DELISTED
Regulus Therapeutics
RGLS
– –
-847,176
Closed -$1.48M
SAGE
79
DELISTED
Sage Therapeutics
SAGE
– –
-108,200
Closed -$860K
SPRO icon
80
Spero Therapeutics
SPRO
$73M
– –
-125,000
Closed -$90K
SPRY icon
81
ARS Pharmaceuticals
SPRY
$532M
– –
-95,290
Closed -$1.2M
TNYA icon
82
Tenaya Therapeutics
TNYA
$170M
– –
-47,319
Closed -$27K
TSHA icon
83
Taysha Gene Therapies
TSHA
$1.86B
– –
-522,500
Closed -$726K
TSVT
84
DELISTED
2seventy bio
TSVT
– –
-429,252
Closed -$2.12M
NVRO
85
DELISTED
NEVRO CORP.
NVRO
– –
-38,000
Closed -$222K
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return

DAFNA Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, DAFNA Capital Management held 86 positions worth $362M, up 2.7% from $353M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

DAFNA Capital Management withdrew a net $13M in Q2 2025, closing 10 positions and reducing 21 holdings. Its most notable exit was 2seventy bio, an estimated $2.12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Compass Therapeutics worth $1.37M.

  • DAFNA Capital Management's largest Q2 2025 buy was Compass Therapeutics: 526,660 shares worth $1.37M.
  • DAFNA Capital Management added most to Blueprint Medicines in Q2 2025, an estimated $1.71M increase.
  • DAFNA Capital Management's biggest Q2 2025 reduction was BioCryst Pharmaceuticals, cutting an estimated $3.17M.
  • DAFNA Capital Management fully exited 2seventy bio in Q2 2025, selling an estimated $2.12M.
  • DAFNA Capital Management's ten largest holdings make up 56% of its $362M portfolio in Q2 2025.
  • DAFNA Capital Management opened 3 new positions and closed 10 in Q2 2025.
  • DAFNA Capital Management's portfolio value rose 2.7% quarter-over-quarter to $362M.

Based on DAFNA Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.